By the End of the Year We Won’t Need Vaccines. So Why Are You Getting Jabbed?
Maybe This Is Why Government Has Been In Such A Hurry
To Vaccinate Everybody, So Vaccine Makers Will Get A Return
On Their Investment Before Competing Technologies Are Introduced
Modern medicine has now come up with a doozy of a pill, and believe it or not, it is being panned as an alternative to vaccination! But in a modern version of “your money or your life?”, it isn’t going to come cheap.
As the first oral antiviral medication for COVID-19, it is likely to gain emergency use authorization without prolonged studies. It may save your life, but it won’t keep you from getting sick. Anything that keeps you from getting sick is not in Big Pharma’s business model.
Zero mortality rate in one study
The pro-drug (metabolizes into a drug), generic name molnupiravir, taken twice a day, demonstrably reduced the need for hospitalization from 14.1% to 7.3% and mortality dropped to zero compared to 8 deaths among 775 patients treated.
Good-bye booster shots and vaccine passports
Good-bye booster shots also. Molnupiravir works against all variants.
Unlike other anti-viral drugs like Remdesivir which must be administered intravenously, molnupiravir can be orally administered.
Molnupiravir is also pannned as a broadl-spectrum anti-viral that halts not only strains of COVID-19 coronavirus but all viruses – it inhibits Chikungunya virus, respiratory syncytial virus, hepatitis C virus, norovirus, influenza-A & B viruses and Ebola virus, and all human coronaviruses.
Needle phobic? Get in line: ramping up production and delivery
Its drugmaker is planning on delivering 10 million courses (5 pills) by the end of 2021 @$712 per course ($142.40 per pill). Without going through any steps of approval, it’s reported the US government has already issued a contract for 1.7 million courses (X $712 =$1.2 billion).
How did it ever get patented with decades of preceding science?
It’s difficult to believe Molnupiravir got a patent. It has been known for decades that C9H13N306 or N4-hydroxycitidine (molnupiravir) induces errors into the virus’s RNA that lead to the demise of virally infected cells.
Unconscionable profit margin
The cost to manufacture Molnupiravir is said to be $17.74 for a 5-pill course of treatment. Its $712 re-sale price is a 40x markup. For comparison, drug companies in India will put molnupiravir on the market at $12 for a 5-day course.
Government funded but turned over to private enterprise
A report posted as TheIntercept.com documents government funding has been involved in the development of molnupiravir.
A list of US-funded patents for molnupiravir funded by government grants can be found online.
Under the Bayh-Dole Act (1980), the federal government can suspend use of patents when government-funded drugs are over-priced. Instead, “government just have it away to private industry with apparently no strings attached.” $35 million of public money was used to develop the drug.
Could be a biological catastrophe
One hitch, drugs in the same class as molnupiravir have been linked to birth defects in animal studies. So, n
Article from LewRockwell